Skip to main content
Caplight Logo









Altay Therapeutics

Altay Therapeutics

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://altaytherapeutics.com

Last Round

Series A

Oct 14, 2026

Est. Valuation

$2.14M

Total Funding Raised

$40.73M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Altay Therapeutics operates in Healthcare & Life Sciences and is based in San Carlos, California. Its latest recorded funding round was a Series A round in October 2026.

Altay Therapeutics is a biotechnology company that develops novel small-molecule inhibitors of transcription factors to treat neuromuscular disorders, cancer, and chronic inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Altay Therapeutics Comparables

Compare Altay Therapeutics with similar companies based on industry and business-model similarity.

Altay Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Myocea, Inc.
86%
Facio BioTherapies
84%
Facio Therapies
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Altay Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 14, 2026
GrantSep 15, 2023
GrantSep 1, 2023
GrantJul 11, 2023
SeedSep 21, 2022
Accelerator
Mar 16, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Osman Nidai Ozes

Founder And Chief Scientific Officer

Founding Team

Ali Ozes

Founder And CEO

Founding Team

Jim Breitmeyer

Chief Executive Officer, Board Director

Executive Team

For institutional investors. Book with your work email.

Altay Therapeutics Investors

Notable investors and investment history

Altay Therapeutics investors
InvestorRounds
A. M. Pappas & AssociatesSeries A
RM Global PartnersSeries A
NIH RADxGrant
Fountain Healthcare PartnersSeries A
HealthCapSeries A
Solve FSHDGrant, Seed
Y CombinatorAccelerator
Book a demo to see all 9 investors

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2026

    $16M round raised

  • Sep 11, 2026

    Monthly visitors grew 67% MoM, reaching 2.3K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • receives_financingOct 14, 2026

    On Oct 14th '26, Altay Therapeutics, Inc. closes a $37M Series A financing co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund, to advance DX5057 through clinical development and support its drug-discovery platform in California.

Book a demo to see all news

For institutional investors. Book with your work email.

Altay Therapeutics Filings

Explore SEC and related filing metadata, where available.

Altay Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Altay Therapeutics's valuation, stock price, and market status.

Is Altay Therapeutics a public or private company?

Altay Therapeutics is a private company.

What is the current stock price of Altay Therapeutics?

Altay Therapeutics is a private company, so its shares have no public market price. Caplight tracks Altay Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Altay Therapeutics worth (valuation)?

Altay Therapeutics's valuation is estimated at $2.1M based on funding round data.

Can I buy Altay Therapeutics stock?

Altay Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Altay Therapeutics's last funding round?

Altay Therapeutics's most recent funding round was Series A on October 14, 2026.

Who are the main investors in Altay Therapeutics?

Key investors in Altay Therapeutics include HealthCap, Solve FSHD, Sound Bioventures.

Will Altay Therapeutics IPO soon?

No public IPO plans have been announced for Altay Therapeutics.

How can I track Altay Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Altay Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range5
Year Founded2019
Last FundingOct 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?